Rohit Borker
About
In The Last Decade
Rohit Borker
30 papers receiving 586 citations
Peers
Comparison fields: 5 of 78
- Pulmonary and Respiratory Medicine 313
- Physiology 157
- Economics and Econometrics 136
- Oncology 100
- Epidemiology 95
Countries citing papers authored by Rohit Borker
This map shows the geographic impact of Rohit Borker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rohit Borker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rohit Borker more than expected).
Fields of papers citing papers by Rohit Borker
This network shows the impact of papers produced by Rohit Borker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rohit Borker. The network helps show where Rohit Borker may publish in the future.
Co-authorship network of co-authors of Rohit Borker
This figure shows the co-authorship network connecting the top 25 collaborators of Rohit Borker. A scholar is included among the top collaborators of Rohit Borker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rohit Borker. Rohit Borker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Cost-effectiveness of Afatinib versus Erlotinib in the First-line Treatment of Patients with Metastatic Non-small Cell Lung Cancer with EGFR Exon 19 Deletion Mutations | 5 |
| 2 | 8 | |
| 3 | 15 | |
| 4 | 18 | |
| 5 | 41 | |
| 6 | 57 | |
| 7 | 8 | |
| 8 | 1 | |
| 9 | COST-EFFECTIVENESS OF PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) COMPARED WITH BSC ALONE IN CHEMOREFRACTORY METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) WITH WILD-TYPE (WT) KRAS TUMOR STATUS IN THE NETHERLANDS | 3 |
| 10 | 12 | |
| 11 | 30 | |
| 12 | 26 | |
| 13 | 18 | |
| 14 | 11 | |
| 15 | 1 | |
| 16 | 8 | |
| 17 | 123 | |
| 18 | 37 | |
| 19 | 25 | |
| 20 | 53 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.